A phase II trial analyzing neoadjuvant PROSTVAC in patients awaiting RP showed an increase in CD4+ and CD8+ T cell infiltration of the tumor, as well as a peripheral immune response to neoantigens in 13 out of the 25 patients [155]. The gene discussed is CD8A; the disease is neoplasm.